Status:
UNKNOWN
Radioisotope and Fluorescence Guidance in Rectal Cancer
Lead Sponsor:
University College, London
Conditions:
Rectal Cancer
Lymph Node Metastasis
Eligibility:
All Genders
Phase:
NA
Brief Summary
A study to investigate if pelvic side wall lymph nodes that remain after neo-adjuvant chemoradiotherapy can be identified intraoperatively using dual radioisotope and fluorescence guidance.
Detailed Description
Background Total mesorectal excision (TME) revolutionised the management of rectal cancer by improving outcomes and standardising surgical technique. When excising mesorectal lymph nodes, most involve...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Primary diagnosis of biopsy-proven rectal cancer
- Scheduled for curative robotic surgery of primary tumour
- Have signed an approved informed consent form for the study
- Be willing and able to comply with the study protocol
Exclusion
- Known allergy or history of adverse reaction to Technetium-99m nanocolloid or indocyanine green
- Pregnant or lactating subjects
- Subjects who, in the Investigator's and/or designee's opinion, have any medical condition that makes the subject a poor candidate for the investigational procedure, or interferes with the interpretation of study results
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05336643
Start Date
January 1 2023
End Date
April 1 2024
Last Update
November 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University College London Hospital
London, United Kingdom